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Supporting Information: 
Dynamic microPET scan. NOD/SCID mouse was intravenously injected with 7.4 MBq 
of 64Cu-DO3A-VS-Cys40-Exendin-4 and then subjected to a 30-min dynamic scan (2 × 1 
min, 3 ×3 min, 2 × 5 min, 1 × 9 min; total of 8 frames) starting right after injection. Five-
minute static PET images were also acquired at 1h after injection. The images were 
reconstructed by 2-dimensional ordered-subsets expectation maximization (OSEM) 
algorithm. 
Solution Stability. The solution stability of 64Cu-DO3A-VS-Cys40-Exendin-4 was 
studied by measuring the radiochemical purity with HPLC after incubation in serum 
solution at 37 oC. The purified product was reconstituted in serum solution to 1 mCi/mL. 
Sample of the resulting solution were analyzed by radio-HPLC at 7 h post incubation. 
Metabolic Stability. The metabolic stability of 64Cu-DO3A-VS-Cys40-Exendin-4 was 
evaluated in a NOD/SCID mouse. Sixty minutes after the intravenous injection of 7.4 
MBq of 64Cu-DO3A-VS-Cys40-Exendin-4, the mouse was sacrificed and liver and 
kidneys were harvested. The liver and kidneys were homogenized using a homogenizer, 
suspended in 1 mL of PBS buffer, and then centrifuged for 5 min at 14,000 rpm. For each 
sample, after the removal of the supernatant, 50% TFA in 100 µL PBS was added to the 
solution, followed by mixing and centrifugation for 5 min. The upper solution was then 
taken and injected for HPLC analysis. The eluent was collected with a fraction collector 
(1.0 min/fraction), and the radioactivity of each fraction was measured with a gamma 
counter. 
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Figure S1. (A) Representative coronal microPET images of a NOD/SCID mouse at 1, 5, 
11, 16, 30, and 60 min after injection of 64Cu-DO3A-VS-Cys40-Exendin-4. (B) Time–
activity curves of heart after intravenous injection of 64Cu-DO3A-VS-Cys40-Exendin-4. 
Data were derived from a multiple time-point microPET study. 
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Figure S2. (A) The HPLC profile of 64Cu-DO3A-VS-Cys40-Exendin-4 at 7 h post 
purification. Metabolic stability of 64Cu-DO3A-VS-Cys40-Exendin-4 in the liver (B) and 
kidneys (C) at 1 h post-injection. 
 
 
